FDA Submits Collection of Information for OMB Review Under Paperwork Reduction Act

Summary

The Food and Drug Administration (FDA) has submitted a proposed collection of information to the Office of Management and Budget (OMB) for review and clearance, as required by the Paperwork Reduction Act of 1995, to report on biological product deviations and human cells, tissues, and cellular and tissue-based deviations in manufacturing.